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Abstract 
 Oncolytic virotherapy is a field dedicated to exploiting viruses in the battle against 
cancer, where their specific cytolytic effects are sorely needed. This work focuses on the 
mechanisms and limitations of oncolytic virotherapy, on the recent advances in the field and on 
the potential oncolytic viruses hold for the future. 
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Abstrakt 
 Onkolytická viroterapie se zaměřuje na využití virů v léčbě nádorových onemocnění, 
Využívá potenciálu některých virů množit se preferenčně v nádorových buňkách a lyzovat je. 
Tato práce se zaměřuje na mechanismy a limitace onkolytické viroterapie, na nedávné pokroky 
v oboru a na budoucí směry výzkumu.  
Klíčová slova: onkolytické viry, onkolytická viroterapie, imunoterapie nádorů, onkologie, 
nádory 
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 For the past at least fifty years, surgery, chemotherapy and radiation therapy were the 
staple standard methods of cancer treatment. Even though the immune system of the human 
body is capable of recognizing and destroying cancer cells, the induction of a specific anti-tumor 
immune response in clinical setting has always eluded the researcher's efforts - right until the 
very recent years, when the tide has turned in favour of cancer immunotherapy. That happened 
mainly thanks to the uncovering of immunosuppressive pathways which tumor cells exploit to 
escape the immune response. The recent advances and successes of cancer immunotherapy are 
briefly reviewed in the first chapter of this work. 
The majority of this paper focuses on a branch of cancer immunotherapy that is showing an 
increasing potential. That is the oncolytic virotherapy which harnesses cytolytic machinery of 
some viruses and their ability to selectively infect and proliferate within tumor cells. The 
following text describes mechanisms of action of oncolytic virotherapy, its hurdles and 
limitations. The recent advances including review of clinical trials and the promises of 




1 Advances in cancer immunotherapy 
 
 The idea of mobilizing the host’s immune system against cancer dates back decades, but 
in the past such efforts yielded only a limited success. The disappointing results of the studies 
investigating this promising idea were caused mainly by an incomplete understanding of 
interactions between the tumor’s and the host’s immune system, most prominently the tumor’s 
capabilities of immune evasion.  
 Thanks to the advances in cancer research, it is now evident that various components of 
the immune system play a crucial role in the recognition and destruction of cancer cells. 
However, despite the fact that the immune system is capable of elimination of malignant cells, 
cancer cells are able to evade the immune response by many mechanisms (Sharma et al. 2011). 
The recognition of multiple tumoral resistance mechanisms in the 1990s (Walunas et al. 1994), 
and, most importantly, the discovery of immune checkpoint pathways utilized to inhibit the 
activity of effector immune cells, led to a development of drugs aimed at these immune 
checkpoints. Ipilimumab, an antibody targeted against CTLA-4 immune checkpoint and 
antibodies targeting PD1-PD-L1 axis gained approval for clinical treatment of melanoma in 
2011 and 2014, respectively (Sharma and Allison 2015). The field of active immunization 
against cancer is far less successful and many so-called cancer vaccines failed in the phase III 
clinical trial. The only product that reached the approval based on phase III clinical trial is 
sipuleucel T, an autologous cell-based therapy approved for the treatment of metastatic 
prostate cancer in 2010 (Gardner, Elzey, and Hahn 2012). 
 The success of check-point inhibitors revitalized the field of cancer immunotherapy, 
which has been experiencing a renaissance in the past decade. Researchers are now 
investigating the uses of various immune components in the battle against cancer, including 
naked and conjugated monoclonal antibodies, bispecific antibodies, immune checkpoint 
inhibitors, pro-inflammatory cytokines, anti-cancer vaccines, adoptive T cell therapies, 
oncolytic viruses and more. The goal of this chapter is to briefly introduce the most prominent 
of the emerging cancer immunotherapies, as these will certainly become a part of combinational 
oncolytic virotherapy treatments.  
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1.1 Monoclonal antibodies 
 
 A range of monoclonal antibodies is developed to target  tumor associated antigens or 
antigens expressed within the tumor milieu such as neovasculature. Native antibodies are able 
to induce target cell killing mainly by complement-dependent cytotoxicity of antibody -
dependent cytotoxicity mechanisms or induce apoptosis of target cell by blocking a  specific 
receptor pathway  (Scott, Allison, and Wolchok 2012). 
 Bispecific antibodies bind to antigens on both tumor cell and effector immune cell 
(mainly T cell) surfaces, bringing them close together and thus inducing an immune response. 
Bispecific T cell engagers (BiTE) and dual-affinity re-targeting (DART) are the two most 
promising classes of bispecific antibodies, with some BiTEs already approved for clinical use 
(Fan et al. 2015).  
 Antibody drug conjugates (ADCs) are monoclonal antibodies linked with cytotoxic 
chemotherapeutics. This approach aims to take advantage of the high antibody-antigen binding 
specificity, which guarantees specific delivery of cytotoxic agents to tumor cells (Marin-Acevedo 
et al. 2018). The selection of the target antigen is therefore one of the most important aspects 
of the ADC therapy. An ideal antigen would be overexpressed by tumor cells, while normal cells 
would exhibit low or no expression of this particular antigen. 
 Immune checkpoint inhibitors aim to disrupt the inhibitory effects malignant cells have 
on immune effector cells by targeting these immune checkpoint pathways, directly binding to 
the receptors or ligands, effectively blocking the inhibition cascade. Some of these have already 
been mentioned. Ipilimumab is a CTLA-4 targeted antibody approved for clinical treatment of 
melanoma, nivolumab and pembrolizumab are PD1-PD-L1 axis targeted antibodies that are 
approved for clinical treatment of melanoma and non-small cell lung cancer (NSCLC) (Sharma 
and Allison 2015). Both CTLA-4 and PD-1 immune checkpoint inhibitors are however expected 
to prove effective against a broader range of malignancies. The major issue of immune 
checkpoint inhibitor therapy (especially CTLA-4 blockade) are adverse effects stemming from 
autoimmune reactions (Hodi et al. 2010). The representative examples of approved drugs of 
each cathegory of monoclonal antibodies are shown in the Table 1. 
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Table 1: Examples of approved antibody-based oncologic drugs. Abs - antibodies, BiTE - bispecific T cell 
engager, DART - dual affinity re-targeting, ADC - antibody-drug conjugate, NSCLC - non-small cell lung cancer. 





Rituximab MabThera® B-cell malignancies 
(Grillo-Lopez et al. 
2000) 
Cetuximab Erbitux® Colorectal cancer (S.-F. Wong 2005) 
BiTEs Blinatumomab Blincyto® B-cell malignancies 































1.2 Cytokine therapy 
 
 Pro-inflammatory cytokines and chemokines attracting immune effector cells compose 
another point of interest for cancer immunotherapy. In particular, IL-12, which has anti-tumor 
effects thanks to its ability to activate NK and T cells, has been proposed as a potential anti-
tumor agent (Lasek, Zagożdżon, and Jakobisiak 2014). IL-2 (Tomala and Kovar 2016) and IL-15 
(Stephenson et al. 2012) have been investigated similarly as they act as an immune system 
enhancer. The major issue of cytokine therapy is a successful delivery of the cytokines to tumor 
bed, as systemic administration is usually associated with high toxicity. Genetically modified 
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viral vectors are used for this purpose (Lebel et al. 2016). Note that viral vectors are replication-
incompetent, which distinguishes them from conventional oncolytic viruses. Linkage of 
cytokines to specific monoclonal antibodies is another approach (immunocytokines).  
 
1.3 Adoptive T cell therapy 
 
 Adoptive T cell therapy represents, next to immune checkpoint inhibitors, the most 
promising immunotherapy. It is now evident that lymphocytes are capable of finding and 
eradicating tumor cells and adoptive T cell therapy aims to put the anti-tumor properties of 
lymphocytes to fight against cancer cells. 
 Tumor infiltrating lymphocytes (TILs) are T lymphocytes carrying specific receptors 
against tumor antigens. In TIL therapy, TILs are first harvested from a surgically removed part 
of the patient’s tumor, then expanded ex vivo in laboratory conditions, while being grown with 
various proinflammatory and immunostimulatory cytokines to reverse the inhibitory 
properties of some lymphocytes (Gilham et al. 2015). After substantial population of T 
lymphocytes is grown, TILs are reinfused back into the patient. Despite the very impressive 
results of TIL therapy (Prickett et al. 2016), a number of challenges need to be resolved before 
this approach can be implemented as a commonplace cancer treatment. Adoptive TIL therapy 
is very time consuming and financially demanding. Furthermore, adoptive TIL therapy has so 
far only been successful against melanoma and no other malignancies. It is speculated that the 
high mutational burden of melanomas compared to other malignant populations contributes to 
this fact (Hinrichs and Rosenberg 2014). The advantages of TILs are their relatively low toxicity 
and their heterogenous specificity, which makes it harder for tumor population to accomplish 
immunological escape. 
 Chimeric antigen receptor T cells (CARs) are genetically modified T cells produced by 
inserting CAR genes to the lymphocyte genome via viral vectors. CAR are essentially monoclonal 
antibodies functioning as the T cell receptor with a high binding specificity to selected tumor 
antigens and can therefore bypass the need of antigen-specific MHC recognition. Adoptive CAR 
therapy yields impressive results for hematological cancers but has yet to show a successful 
application in solid tumors (Yu et al. 2017). The most severe adverse effect of CAR therapy is 
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the relatively high toxicity culminating in the so-called cytokine release syndrome (CRS). This 
is a potentially fatal condition caused by the massive release of cytokines (Lee et al. 2014). Other 
disadvantages include difficulties of targeting CARs to tumor sites, immune suppressive tumor 
microenvironment and lack of ideal tumor antigens. 
 TCR gene modified T cell therapy utilizes genetically modified T cells, which has been 
inserted with a modified TCR gene which recognizes specific tumor neoantigens presented by 
the HLA molecules. A potentional advantage of TCR gene therapy over CAR is that modified TCR 
can be targeted against intracellular neoantigens presented on HLA, whereas CAR can only 
target surface antigens. Probably the biggest challenge of this approach is the selection of 
antigens and successful long-term expression of the modified TCR gene (Govers et al. 2010).  
1.4 Cancer vaccines 
 
  Similarly to prophylactic vaccines against infectious agents, therapeutic cancer vaccines 
seek to induce an antigen-specific immune response by delivering and presenting tumoral 
antigens to host’s immune cells. Specifically, they are designed to enlarge the T cell populations 
capable of recognizing and eradicating malignant cells. Cancer vaccines are classified by their 
method of antigen delivery: tumor cell vaccines (K. Zhang et al. 2017), genetic vaccines (Guo et 
al. 2013), dendritic cell vaccines (Sabado and Bhardwaj 2013) and peptide vaccines (Ueda et al. 
2017), which count among the most prominent. 
 The major obstacle to the successful utilization of cancer vaccines is the selection of a 
suitable tumor antigen. Such an antigen should be overexpressed on malignant cells, but normal 
cells should evince low or no expression. It also has to be noted that tumor cells are often 
heterogenous and so an immune response against one antigen doesn’t guarantee an immune 
response against the whole tumor. Moreover, tumor cells can mutate in the genes encoding the 
particular epitopes or stop expressing the antigen altogether, thus evading the immune 
response (Fenoglio et al. 2013). Finally, in order to be successful, cancer vaccines have to break 





1.5 Oncolytic viruses 
 
 This very promising emerging cancer immunotherapy utilizes viruses with natural 
tropism for malignant cells, which are capable of debulking the tumor beds and inducing an anti-




2 Oncolytic virotherapy 
 
 In 2011, Hanahan and Weinberg described the so-called hallmarks of cancer, such as 
continuous proliferation, disruption of cellular apoptotic apparatus and defective 
immunological pathways (Hanahan and Weinberg 2011). Many of those characteristics make 
malignant cells an ideal target for a variety of viruses, which prefer to replicate in such cells, 
effectively killing them. Thanks to their natural tropism for cancer cells and their lytic activity, 
these viruses were dubbed oncolytic viruses and researchers had been trying to employ them 
in the battle against cancer for almost a century, but oftentimes with disappointing results.   
 However, ever since more knowledge about the mechanisms of oncolytic virotherapy 
and interactions of cancer cells and host’s immune system has been uncovered, the tide has 
turned in favor of researching new immunotherapies involving oncolytic viruses. In particular, 
the approval of Talimogene laherparepvec (T-VEC) in 2015 as the first oncolytic agent in clinical 
use in the US and Europe (Ledford 2015) has boosted the interest in developing new oncolytic 
viruses. 
 The goal of this chapter is to review mechanisms and limitations of oncolytic virotherapy, 
as well as to present recent new approaches of improving oncolytic viruses and finally to show 
some of the most promising virotherapies in clinical development. 
 
2.1 Mechanisms and limitations of oncolytic virotherapy 
 
  The aim of this chapter is to clarify the exact mechanisms of oncolytic activity of 
oncolytic viruses as well as to present the obstacles and challenges that stand before the modern 
oncolytic virotherapy. 
 The most defining characteristic of oncolytic viruses is their ability to infect and kill 
cancerous cells, but not normal tissue. Their natural tropism for malignant cells can be 
explained by the overexpression of entry receptors, which viruses use to attach and get into the 
cytoplasm, by cancer cells and also by the favorable environment for viral replication 
established by the "hallmarks of cancer" as noted above. 
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 For the most part of the 20th century, oncolytic viruses were attractive because of their 
ability to directly replicate in cancer cells and killing them afterwards. However, in the late 
1990s, it started to be apparent that, sometimes, viral infections induced antigen-specific 
immune responses against tumors and oncolytic viruses thus effectively acted as cancer 
vaccines (Toda et al. 1999). Indeed, in the following years, the induction of immune response 
became a much more appreciated trait of oncolytic virotherapy and, today, its importance 
eclipses even that of a direct cell killing. 
 The nature of cellular death plays a role in the magnitude of induction of immune 
response. For example, necrosis is more immunostimulatory than apoptosis. During stress-
induced cellular death, the so-called damage-associated molecular patterns (DAMPs) are 
released from the dying cell and are subsequently picked by the immune cells, which become 
activated and induce an inflammatory response. Some examples of DAMPs are ATP, HMGB-1, 
calreticulin or uric acid. Moreover, such destroyed cells expose neoantigens, which were before 
inaccessible for the innate immune cells. These neoantigens can then be recognized by the cells 
of the immune system and lead to a new antigen-specific immune response even in the distant 
tumor sites which were not infected by the virus. The induction of the so-called immunogenic 
cell death in tumors which induces a tumor-specific immune response seems to be the major 
mechanism of antitumoral activity of oncolytic viruses. A simplified scheme of the effects of 




Figure 1: Activities of oncolytic virotherapy. The approach takes advantage of natural tropism of oncolytic 
viruses against tumor cells and combines both their cytolytic and immunogenic activities. Adopted from 
(Russell and Peng 2017). 
 Oncolytic viruses can sometimes infect neighbouring cells that are not malignant but 
contribute to the immunosuppressive microenvironment in the tumor (e. g. myeloid-derived 
suppressor cells, MDSCs). These cells can also by killed by the so-called bystander effect, when 
the released granzymes and perforines from cytotoxic T cells, originally meant for cancerous 
cells, reach the neighbouring tissue. Increased concentration of immunostimulatory and 
cytotoxic cytokines also contributes to this effect (Schietinger et al. 2010). 
 Some oncolytic viruses were also found to target tumor vasculature, infecting endothelial 
cells and causing thrombosis in tumor vessels (Breitbach et al. 2011; Breitbach et al. 2013). 
 In addition, oncolytic viruses induce an innate immune response as they carry the 
pathogen-associated molecular patterns (PAMPs), for example, double-stranded viral RNA. The 
recognition of PAMPs by their receptors (for example TLR or RLR receptors) in both infected 
cells and immune cells leads to an inflammatory response, which is in turn important for 
establishing a stable antigen-specific immune response, because the recognition of PAMPs, 
DAMPs and proinflammatory cytokines guarantees the activation of costimulatory signals to the 
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effector immune cells and helps to break the immunosuppressive tumor microenvironment 
(Maisonneuve et al. 2014). 
 The most important of the innate immune responses against viral infection is the Type I 
interferon (IFN) pathway. After the infected cells recognize PAMPs by their PAMP receptors, 
they produce and release type I IFNs, which activates PKR (protein kinase R) in neighbouring 
cells. If PKR recognizes dsRNA or other viral PAMPs, it terminates cellular proteosynthesis, 
effectively killing the cell. However, since PKR pathway recruits p53 and stops cellular 
proliferation, it is often defective in cancer cells (Clemens 2004). 
 The activation of anti-viral IFN pathway by the cancer cells therefore acts as a double-
edged sword; while its activation leads to viral clearance, it also stops cellular proliferation and 
induces inflammatory response. The dysregulation in the IFN pathway on the other hand makes 
it easier for oncolytic viruses to replicate in the tumor bed. The mechanism of facilitated viral 
infection of cells with defective IFN pathway is depicted in Figure 2. 
In short, the oncolytic activity of oncolytic viruses consists of 4 parts: (i) direct cytolytic 
effect on malignant cells, (ii) the release of proinflammatory and cytotoxic cytokines, (iii) 
activation of innate immune response, which, among other things, recruits NK cells that 
preferentially kill cells with downregulated MHC expressions, as is common for cancer cells and, 
finally, (iv) by inducing antigen-specific adaptive immune response recruiting CD4+ and CD8+ T 
cells (Cassady et al. 2016). 
Thanks to the ongoing attenuation of viral strains and discoveries of new, safer oncolytic 
viruses, the main struggle of oncolytic virotherapy in the 20th century - uncontrolled virulence 
with fatal adverse effects - is almost resolved. Nowadays, oncolytic virotherapy is stunted 
mainly by the premature viral clearance. In other words, it is difficult to find balance between 
the anti-tumor responses of the host's immune system and its anti-viral activity. The immune 
system has to be potent enough to fight malignancies, however its activity sets back or 




Figure 2: Facilitated viral infection in cells with defective immune pathways. (a) In healthy cells, detection 
of viral proteins or nucleic acids by Toll-like receptors (TLRs) or RIG-1 like receptors (RLR) activates a signalling 
cascade that leads to upregulated expression of proinflammatory cytokines and type I interferons. IFNs are 
autocrine and paracrine mediators that activate Janus kinase (JAK) through the IFN receptor (IFNR). JAK in 
turn activates STAT cascade inducing the expression of protein kinase R (PKR). PKR, activated by viral nucleic 
acid, aborts cellular proteosynthesis and promotes apoptosis, thus limiting viral spread. (b) In cancer cells, 
elements of immune pathways are defective or downregulated. In such cells, it is harder to detect viral 
infection, because TLRs and RLRs are often downregulated. Furthermore, type I IFN expression is often 
aborted in malignant cells as IFN cascade promotes cellular apoptosis. Oncolytic viruses exploit this 
characteristic of cancer cells for easier infection and replication. In the depiction, various types of viruses are 
depicted close to the elements that are known to be responsible for viral elimination. IFN – interferon, MYD88 
– myeloid differentiation primary response protein, NDV – Newcastle disease virus, STAT -signal transducer 
and activator of transcription, TRAF – TNF-associated factor, VSV – vesicular stomatitis virus. Adopted from 
(Kaufman, Kohlhapp, and Zloza 2015). 
 This problem is the most apparent obstacle of the systemic delivery of oncolytic viruses. 
Intratumoral injections of viruses are common practice, but, if a systemic, intravenous delivery 
could be achieved, the virus would potentially be able to infect all disseminated tumor sites, 
which would greatly enhance its efficacy. Moreover, visceral or bone-residing tumors may not 
be accessible for intratumoral injection. When administrated intravenously, the dose of the 
active virus particles is greatly diluted and then further reduced by sequestration in liver and 
spleen. Innate immune mechanisms also work to get the virus out of bloodstream, eliminating 
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a number of viral particles by antibodies and complement proteins. Moreover, rapid viral 
clearance occurs if pre-existing virus-specific antibodies are present in the blood. That is often 
the case of viruses that cause common infections, which are often contracted at early age (HSV, 
reovirus) or of viruses that people are getting vaccinated against, such as measles virus. 
 The size and heterogenicity of the tumor also pose a barrier to a successful virus 
distribution. Stromal cells, for example tumor associated fibroblasts, can get infected but the 
virus doesn't undergo the replication cycle in them. Such cells therefore act as decoys, further 
reducing the dose of viral particles competent to infect tumor cells (Lopez et al. 2009). 
 A some studies with surprising results made clear that some tumors mutated so that they 
can upregulate the IFN pathway without suffering from any of its anti-tumor effects (Khodarev, 
Roizman, and Weichselbaum 2012). Such tumor cells are equipped with a potent anti-viral 
response, which doesn't reduce their proliferation potential, and that makes oncolytic 
virotherapy unsuitable for treating such malignancies. 
 Finally, even if a viral infection successfully induces an antigen-specific adaptive immune 
response, there is a concern that the immune response would be targeted primarily against the 
immunodominant viral antigens and this anti-viral response would eclipse any commencing 
anti-tumor response (Cassady et al. 2016). 
 
2.2 New approaches in oncolytic virotherapy 
 
 The goal of this chapter is to briefly review various modern ways of overcoming the 
obstacles associated with viral therapy and methods for improving oncolytic virus efficacy. In 
short, these approaches focus on four aspects of virotherapy: (i) attenuation of oncolytic viruses 
- adapting viruses so that they target preferentially cancer cells while omitting normal tissue, 
thus increasing their safety, (ii) enhancing the cytolytic activity of oncolytic viruses, (iii) 
increasing the immunostimulatory potential of virotherapy and finally (iv) improvement of viral 
biodistribution. 
 Oncolytic viruses can be attenuated in a number of ways. Most of them focus on 
improving their ability to replicate in malignant cells, but worsening their ability to infect 
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normal tissue, thus further specializing the virus strains that already possess natural tropism 
for cancer cells. 
 One of such ways is the so-called directed evolution - serial passaging of viruses in human 
tumor cell lines. The nature of RNA viruses is especially suitable for this approach, while DNA 
viruses are difficult to adapt this way, as the rate of mutagenesis of the viral DNA genome is 
much lower than that of RNA viruses (Sanjuán et al. 2010). After a successful parallel passaging 
of viruses in tumor cell lines, their genomes are sequenced and common mutations increasing 
virus' specialization to cancer cells are sought after (Sanjuán and Grdzelishvili 2015). In one 
such study, different adenovirus serotypes were passaged in human colon cancer cell lines, 
resulting in the emergence of a virus strain with a highly improved replicative potential in 
cancer cells - ColoAd1 (Kuhn et al. 2008).  
 Some viruses can be specifically engineered to target surface molecules overexpressed 
on cancer cells as their entry receptors. For example, Ad5/3-δ24 has been engineered to bind 
integrins overexpressed on the cells of ovarian carcinoma (You et al. 2001) and measles virus 
has been engineered to target the carcinoembryonic antigen (CEA) a common surface receptor 
of various cancers (Hammond et al. 2001). 
 Another approach is to impair viral ability to block cellular anti-viral responses, which 
are normally active in healthy cells but dampened in cancer cells. HSV-1 was attenuated this 
way by the deletion of ICP34.5 and US11 genes, which participate in blocking of PKR 
phosphorylation (Poppers et al. 2000). Such virus strains can then replicate only in cells with 
broken PKR pathway. Similarly, B18R gene of vaccinia virus blocks Type I IFN signaling. By the 
deletion of B18R, vaccinia virus can only competently replicate in cancer cells with defective 
IFN signaling pathway (Kirn et al. 2007). Adenoviral E1B protein can bind and inactivate p53. 
Both ONYX-15 and H101, which are adenoviruses used in clinical trials, have deletion in E1B, 
decreasing their potential to replicate in healthy cells which undergo p53-mediated apoptosis 
after being infected (Heise et al. 1997; Yuan et al. 2003). On the other hand, nearly a half of all 
the human cancers have defective p53 pathway, making them susceptible to viral infection. 
 Viruses can be further specialized by making their replication cycle dependent on tumor 
environment. For example, the deletion of TK (thymidine kinase) gene in vaccinia virus, renders 
vaccinia virus to only be able of replication in cells with high concentrations of nucleotides, 
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which means actively dividing cells (Buller et al. 1985; Guse, Cerullo, and Hemminki 2011). The 
rate of gene expression can be changed by putting particular viral genes under the control of 
specific promoters, that are more active in cancer cells. For example, promoters of the prostate-
specific antigen (PSA), which is upregulated in prostate cancer cells, or human telomerase 
transcriptase (TERT), which is an enzyme active in most of human cancers, can be inserted in 
adenoviruses to control the expression of the E1A gene (Y. Chen et al. 2001; Chang et al. 2009). 
E1A can also be put under the control of the hypoxia-induced transcription factor HIF-1α, 
making them preferentially replicating in hypoxic environments, such as the interiors of most 
tumors (Post et al. 2007).  
 Finally, viruses can be genetically modified to encode the so-called miRNA targeting 
sequences (miRTS) in their 3' untranslated regions (UTR). The miRTS bind cellular microRNAs, 
repressing the viral replication. Measles virus was modified this way to target glioma cells with 
downregulated miR-7 expression, while blocking replication in normal neurons with 
upregulated miR-7 expression (Leber et al. 2011). 
 Methods of improving the cytolytic activity of viruses are also being developed. Gene 
sequences, that are inserted into viral genomes and, that after expression, make cells more 
susceptible to cellular death or clearance by the immune system are called suicide genes. A 
number of those have been successfully inserted in oncolytic viruses with proven efficacy 
effects. 
For example, oncolytic viruses can be engineered to express Fas ligand (Sathaiah et al. 
2012), p53 (Van Beusechem et al. 2002) or pro-apoptotic TRAIL or TNF-alpha (Sova et al. 2004; 
Hirvinen et al. 2015). One of the gene products with direct cytotoxic effects is, for example, the 
adenovirus death protein (ADP). ADP participates in final stages of adenoviral infection, it has 
cytolytic effects and is crucial for the release of viral particles. Overexpression of ADP in 
oncolytic adenoviruses can thus increase their efficacy (Doronin et al. 2000). Another 
incorporated cytotoxic suicide gene is the bacterial cytosine deaminase (CD), which transforms 
5-fluoro-cytosine into cytotoxic 5-fluoro-uracil (Freytag et al. 2003). Oncolytic viruses can also 
be engineered to target tumor vasculature by expressing VEGF inhibitors (Z. Zhang et al. 2005; 
Gholami et al. 2014). 
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 As is true for the most of immunotherapies, the ultimate goal of oncolytic virotherapy is 
to trigger the antigen-specific adaptive anti-tumor immune response of the host's immune 
system. Today, there are a number of ways of improving the immunostimulatory effect of 
oncolytic viruses. Most of them consist of inserting genes encoding proinflammatory cytokines 
or T cell costimulatory molecules into viral genome. 
  One of the most common inserts is the gene for GM-CSF. GM-CSF attracts DCs, which 
migrate to tumor bed and load and subsequently present TAAs to effector T cells. GM-CSF had 
been inserted, for example, into HSV-1 oncolytic viruses, most notably T-VEC. Moreover, T-VEC 
has a deletion of the viral ICP47 gene (Rehman et al. 2016). Normally, ICP47 blocks TAP, which 
is a transporter delivering degraded peptides from cytoplasm into the ER, where they bind to 
MHC glycoproteins. Deletion of ICP46 should thus increase antigen presentation. 
 Additionally, oncolytic viruses can be engineered to express proinflammatory cytokines 
such as IL-12 or IL-4 (R. J. Wong et al. 2004; Post et al. 2007), chemokines such as CCL5 or CCL3 
(Li et al. 2011) or costimulatory molecules such as CD40 ligand (Galivo et al. 2010). Special cases 
are oncolytic viruses expressing tumor associated antigens. These viruses effectively act as 
oncolytic vaccines (Bridle et al. 2010). 
 One of the major obstacles of oncolytic virotherapy is the premature clearance of the 
virus by the immune system. This is an important setback for the development of systemic 
delivery of viral therapeutics. Rapid viral clearance by pre-existing antibodies can be 
circumvented when using other serotypes of the particular virus. However, this only works for 
viruses against whom immune system develops antibodies that don't exhibit cross-immunity 
against other serotypes (adenoviruses or vesicular stomatitis virus) and viral particles still face 
other obstacles in biodistribution. Therefore, more sophisticated methods have to be employed. 
 Coating the surface of viral particles in polymers, liposomes, nanoparticles, calcium 
residues and, most notably, PEG (polyethylene glycol), had been shown to reduce sequestration 
in the liver and to increase systemic toxicity of the virus (J. Chen et al. 2016; Tesfay et al. 2013). 
A method which would use infected cells as systemic carriers is also being researched. 
Autologous cells (for example mesenchymal stem cells or dendritic cells) can be infected ex vivo 
and then reinfused back to the patient, functioning as cell carriers (Mader et al. 2009). 
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 Even if virus successfully infects a tumor site, its spread is often impaired by tumor size 
and heterogenicity. Therefore, some oncolytic viruses were engineered to express ECM-
degrading enzymes, such as hyaluronidase (Guedan et al. 2010). Others were engineered to 
express fusogenic membrane proteins, infecting neighbouring cells by creating syncitia rather 
than spreading through the tumor microenvironment (Ebert et al. 2004). 
 Oncolytic viruses can also be creatively utilized for cancer imaging. The field is currently 
in a dire need of a non-invasive assessment of biodistribution of oncolytic viruses and, most 
importantly, a way of detecting tumor origin and metastases. Thanks to its large 192 kbp long 
genome, vaccinia virus was recently utilized for such purpose (Haddad 2017). Vaccinia virus 
can be equiped with the so-called reporter genes which can make such specific non-invasive 
method of cancer imaging possible. The reporter genes include GFP, human norepinephrine 
transporter, human sodium-iodide transporter, Renilla luciferase or human somatostatin 
receptor 2 (N. Chen and Zhang 2009; McCart et al. 2004).  An example of molecular imaging 
utilizing genetically modified vaccinia virus is shown in Figure 3. 
 
 
Figure 3: Deep tissue and optical imaging of tumors utlizing GLV-1h153 construct of vaccinia virus in mice 
bearing PANC-1 xenografts (Haddad et al. 2012). The virus was modified to express GFP, human sodium 
iodide symporter (hNIS) and Ruc genes. A combination of imaging techniques can show the sites of the tumor 
and metastases, which had been infected by the said virus, thus allowing for a precise and non-invasive way 
of tumor detection. CT-PET- computed tomography-positron emission tomography, GFP – green fluorescent 
protein, hNIS – human sodium iodide symporter, P – photons or photon flux, PANC-1 – a human pancreatic 




2.3 Oncolytic viruses in clinical development 
 
  Viruses are incredibly diverse in their characteristics, tropism, biodistribution, 
virulence and many other factors. Similarly, due to their high mutational burden, human tumors 
are genetically variable even to the point at which each one of the tumors can be considered 
unique. It is therefore unlikely that one oncolytic virus would become the best candidate for 
general cancer treatment, and so it is reasonable to develop additional oncolytic 
virotherapeutics from a variety of virus strains (Russell and Peng 2017). Moreover, a strong 
curative potential may lie in a therapy utilizing the combination of oncolytic viruses. As of today, 
a variety of oncolytic viruses is being researched and evaluated in clinical trials. An introduction 
of some of the most prominent types of oncolytic viruses can be found in this chapter. A brief 
overview of some examples of the ongoing or recently conducted trials can be found in Table 2 
at the end of the chapter. 
 
2.3.1 Herpes simplex virus 
 
 Herpes simplex viruses, and particularly HSV-1, are one of the most widespread kinds of 
viruses currently researched as potential virotherapeutics. T-VEC, first oncolytic virus approved 
for cancer treatment in the US and Europe, is an HSV-1 virus. As Russell and Peng state in their 
review: "... T-VEC is an ideal intratumoral cancer vaccine. It spreads locally within the injected 
tumor and kills tumor cells by in situ necroptosis, causing them to release tumor antigens, viral 
antigens, damage-associated molecular patterns (DAMPs), and GM-CSF, providing what is 
possibly a near-perfect environment for activated APCs to phagocytose a mixture of viral and 
tumor antigens for presentation to CD4+ helper and CD8+ cytotoxic T cells in the regional lymph 
nodes." (Russell and Peng 2017). 
    HSV-M032, engineered to overexpress IL-12 in tumor sites, enters a Phase I clinical trial 
to treat patients suffering from glioblastoma (Patel et al. 2016). HSV-G207 is attenuated by 
deletion of the ICP34.5 region and by mutation of the ICP6 gene, which impair its neurovirulence 
in normal cells. It is a promising candidate for the treatment of brain tumors and it enters Phase 





 ONYX-15 is an adenovirus targeted to cause lysis of cells with defective p53 pathway. It 
was approved for cancer treatment in China in 2006 (Garber 2006), but its development in the 
US and Europe was stopped due to the unconvincing results. 
 Ad-CG0070 is a genetically modified adenovirus expressing GM-CSF and targeted against 
cells with an aberrant Rb-pathway (Ramesh et al. 2006). It was evaluated in Phase I trial for the 
treatment of bladder cancer (Burke et al. 2012), showing tolerable safety profile and oncolytic 
activity. 
 ONCOS-102 is a GM-CSF expressing adenovirus. In 2018, it entered Phase I/II clinical 
trial focused on evaluating the safety of combination of ONCOS-102 with DC vaccine in men with 
metastatic prostate cancer. The trial is conducted by the Urology Clinic of the University 
Hospital in Motol, Prague (NCT03514836). 
 
2.3.3 Vaccinia virus 
 
  A vaccinia virus based GL-ONC1 was evaluated for treatment of patients suffering from 
head and neck cancer in combination with radio- and chemotherapy, showing sufficient safety 
profile (Mell et al. 2017). 
 JX-594 (Pexa-Vec) is a highly promising TK- vaccinia virus based oncolytic vector 
engineered to express GM-CSF. JX-594 was evaluated in a Phase II clinical trial against 
hepatocellular carcinoma, in which immune responses were observed in injected but also in 




 Coxsackievirus is an RNA virus belonging to the family Picornaviridae. 
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 CVA21 is an oncolytic Coxsackievirus targeting DAF and ICAM-1 complex as its receptor 
(D. R. Shafren et al. 1997). Expression of both DAF and ICAM-1 is upregulated in various cancers, 
including melanoma (Cheung et al. 1988). CVA21 had been used in a Phase II clinical trial to 
treat advanced melanoma (Andtbacka et al. 2015). The trial proved its efficacy and safety, as the 
therapy didn't induce any serious adverse effects. 
 
2.3.5 Newcastle disease virus 
 
 NDV is an avian virus non-pathogenic for humans, with proven oncolytic and 
immunostimulatory effects in human patients. 
 In a Phase I trial NDV PV701 was tested for the treatment of solid tumors unresponsive 
to chemotherapy (Pecora et al. 2002). PV701 caused no severe adverse effects, but responses in 
tumor beds were observed. Additionally, electron microscopy of a tumor sample taken 11 




   Probably the most prominent of the oncolytic reoviruses is Reolysin, which has already 
been a subject of several studies. In one of the most recent clinical trials, Reolysin was tested in 
combination with chemotherapy for treatment of breast cancer. It was reported that Reolysin 
caused a statistically significant improvement in overall survival (Bernstein et al. 2017). In a 
Phase II clinical study Reolysin plus chemotherapy was evaluated in treatment of NSCLC, with 
89 % of the treated patients experiencing clinical benefit (Villalona-Calero et al. 2016). 
 It has to be noted though, that the responses of the improvement in OS tend to be 
delayed, as Reolysin acts mainly as an immunostimulatory agent rather than a cytolytic one 
(Fountzilas, Patel, and Mahalingam 2017). 
 Moreover, reovirus might be a promising candidate for the treatment of brain tumors. In 
a recent study, an oncolytic reovirus was shown to be able to cross the blood-brain barrier after 
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intravenous administration and to successfully infect brain tumors of the treated patients 
(Errington-Mais et al. 2018). 
 
2.3.7 Measles virus 
 
    Measles virus propagates between cells by fusing with membranes of neighbouring 
cells and creating syncitia. This could prove beneficial for its biodistribution in the tumor 
microenvironment. 
 MV-NIS, a measles virus expressing human sodium-iodide symporter, was evaluated in 
a Phase I study as a treatment of ovarian cancer non-responsive for chemotherapy. The 
treatment caused no severe adverse effects and the induction of anti-tumor immune response 
was reported. The accumulation of virus in tumor bed was confirmed thanks to functional 
imaging (Galanis et al. 2015). 
 
2.3.8 Other viruses 
 
 A number of oncolytic viruses in clinical development and many recent clinical trials 
have been omitted in this chapter, as this work focuses on the general principles of oncolytic 
virotherapy. To present at least a hint of the full picture, it has to be mentioned that parvoviruses 
(Geletneky et al. 2014), poliovirus (Goetz et al. 2011), Seneca Valley virus (Rudin et al. 2011) 
and even retroviruses (Cloughesy et al. 2016) are being researched for their oncolytic activity. 
Parvoviruses are especially interesting for the treatment of brain tumors, as they proved 
capable of crossing the blood-brain barrier (Hajda et al. 2014). 
 
Table 2: Examples of some recent trials evaluating the safety and efficacy of oncolytic virotherapies. 
NSCLC – non-small cell lung carcinoma. 
Virus type Name Indication Stage Reference 
Herpes 
simplex 
HSV-M032 Glioblastoma Phase I (Patel et al. 2016) 




Ad-CG0070 Bladder cancer Phase I (Burke et al. 2012) 









Phase II (Heo et al. 2013) 
Coxsackievirus CVA21 Melanoma Phase II (Andtbacka et al. 2015) 
Reovirus Reolysin® 
NSCLC Phase II 
(Villalona-Calero et al. 
2016) 
Breast cancer Phase II (Bernstein et al. 2017) 
Measles virus MV-NIS Ovarian cancer Phase I (Galanis et al. 2015) 
 
2.4 Oncolytic viruses in combination with other cancer treatments 
 
  Despite their oncolytic potential, oncolytic viruses were rarely shown to cause a long-
term regression of the disease by themselves. It is therefore almost certain, that in clinical 
practice, oncolytic virotherapy will be used in tandem with other cancer treatments. A number 
of studies researching the efficacy of oncolytic viruses in combination with other agents have 
already been done, this chapter aims to introduce some of them and the potential approaches 
of combinational therapy. 
  Cyclophosphamide (CPA) is an immunosuppressant shown to reduce the number of 
innate immune cells and Treg cells in the patient and thus partially dampening the effects of 
immunosuppressive cells in tumor microenvironment (Thomas et al. 2008). Moreover, it lowers 
the levels of antibodies in patient's blood. Cyclophosphamide was therefore utilized in 
combination with oncolytic viruses in hopes of stronger induction of anti-tumor immune 
response. Indeed, in a study employing vaccinia virus and cyclophosphamide in an animal 
model, stronger anti-tumor immune response and better viral distribution in tumors were 
reported (Hofmann, Weibel, and Szalay 2014). 
 Histone deacetylase inhibitors are capable of dampening the antiviral immune response 
and thus improving the spread of the virus (Alvarez-Breckenridge, Kaur, and Chiocca 2009). 
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 To increase the rate of crossing of viral particles from blood vessels into tumor beds and 
so improving viral delivery, a number of studies employing vasoactive agents have been made. 
The agents in question were, for example, histamine, nitroglycerin (Bilbao et al. 2000) or local 
hyperthermia (Eisenberg et al. 2010). 
 Another obstacle of viral spread is the size of the tumor and especially the extracellular 
matrix (ECM) slowing the spread of viral particles between tumor cells. Hyaluronidase or 
collagenase, ECM-degrading enzymes, were used for pre-degradation of tumor ECM in hopes of 
increasing viral distribution (Ganesh et al. 2008). 
 Tyrosine-kinase inhibitor sunitinib is an antiangiogenic agent which can increase anti-
tumor immunity (Bose et al. 2011). It was also shown to increase the rate of replication of 
vesicular stomatitis virus (Jha et al. 2013). Sorafenib, another tyrosine-kinase inhibitor, showed 
synergistic effects with Pexa-Vec when used in combinational tumor treatment (Heo et al. 
2011). 
 The most reasonable combination is of course the tandem of oncolytic viruses with 
already established cancer therapies. Therefore, a number of studies were made to evaluate the 
safety profile and efficacy of oncolytic viruses in combination with surgery, chemotherapy and 
radiotherapy (Lolkema et al. 2011; Mell et al. 2017). Vaccinia virus showed synergistic effects 
and increase in median survival when used with radiotherapy (Wilkinson et al. 2016). 
 Another approach is to combine oncolytic viruses with cellular therapies. For example, a 
DC vaccine was combined with oncolytic vaccinia virus expressing T cell attracting chemokines 
(Li et al. 2011). Oncolytic virotherapy had also been evaluated in combination with adoptive T 
cell therapy utilizing transgenic TAA-specific T cells (Rommelfanger et al. 2012). Vaccinia virus 
was also combined with CAR T cells with synergistic effects in a mouse model of solid tumor 
(Nishio et al. 2014). 
 Another logical approach is to combine oncolytic viruses with the rising star of cancer 
immunotherapy - immune checkpoint inhibitors. Vaccinia virus showed improved efficacy 
when combined with CTLA-4 inhibitors, but the timing of the administration of CTLA-4 
inhibitors was important (Haddad 2017). If a dose of oncolytic virus was injected on the same 
day that immune checkpoint inhibitor therapy started, the oncolytic effect of virus was 
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dampened. The best results were achieved when administrating CTLA-4 inhibitors three days 
after the start of oncolytic virotherapy. 
 Tumor cells overexpressing PD-L1 are more susceptible to treatment with immune 
checkpoint inhibitors (Gordon et al. 2014). Oncolytic viruses induce expression of IFN, which in 
turn upregulates expression of PD-L1 (Bellucci et al. 2015). Oncolytic virotherapy could 
therefore prime for immune checkpoint blockade therapy, as was shown in a case of reovirus 
against brain tumors (Errington-Mais et al. 2018). CVA21 and pembrolizumab were combined 
to treat melanoma (D. Shafren et al. 2017) and Reolysin plus PD1 inhibitors prolonged the 
overall survival of mice suffering from melanoma (Rajani et al. 2016). Moreover, oncolytic 
viruses can be engineered to express antibodies against immune checkpoint receptors, which 
led to enhanced anti-tumor activity in case of measles virus (Engeland et al. 2014). 
 Finally, some oncolytic viruses could be combined with other oncolytic viruses. Vesicular 
stomatitis virus in combination with vaccinia virus increased the median survival in a mouse 
model (Le Boeuf et al. 2010). Using two different oncolytic viruses in a subsequent fashion could 
also circumvent the problem of immunodominant viral antigens. A therapy with vesicular 
stomatitis virus was more effective if the host's immune system had first been primed with an 
adenovirus expressing TAAs, thus increasing the anti-tumor immune response at the expense 
of anti-viral immune response (Bramson et al. 2013). 
 While combinational therapy holds a great potential, it also brings a number of 
challenges. For example, oncolytic viruses prefer to replicate in dividing cells, but chemotherapy 
kills most proliferating cells. The leaky vasculature improves the viral distribution to the tumor 
and anti-angiogenic therapy could therefore be antagonistic. While low dose CPA treatment 
depletes Treg cells and increases anti-tumor immune response, it also promotes anti-viral 
immune response. The administration of high doses of CPA on the other hand, causes 
widespread immune depletion and enhances viral spread, but dampens anti-tumor immunity. 
The usage of immune checkpoint inhibitors in combinational therapy could unleash anti-viral 
response responsible for premature viral clearance (Chiocca and Rabkin 2014). 
 Nevertheless, the studies strongly suggest that combining oncolytic viruses with other 






 Oncolytic virotherapy has made a long journey in the past seventy years. Despite the 
often-disappointing results of the trials in the 20th century, the approval of T-VEC proved that 
oncolytic viruses have a real potential to become a cancer treatment in clinical practice. 
Moreover, it seems that a number of new oncolytic viruses are soon to be approved for clinical 
use. In particular, JX594 (Pexa-Vec) for the treatment of hepatocellular carcinoma, adenovirus 
CG0070 for the treatment of bladder cancer, Reolysin as an agent against head and neck cancer 
and HSV-1 G47δ for glioblastoma treatment (Lundstrom 2018). The field of oncolytic 
virotherapy still faces many challenges. First of all, viruses need to be further adapted to 
improve their efficacy and specific targeting of cancer cells. Secondly, researchers have to 
evaluate the myriad of possible combinations of oncolytic viruses with other cancer therapies 
to successfully determine the right treatment for patients suffering from various types of cancer. 
 But despite all the obstacles, the recent uplifting results of oncolytic virotherapy could 
start a new era of cancer treatment. And, alongside other immunotherapies, oncolytic viruses 
could enrich the current therapeutic portfolio of anti-cancer drugs and strategies with the hope 
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